2023-05-03 13:47:58 ET
Chinese tech giant Baidu ( NASDAQ: BIDU ) said on Wednesday that an algorithm created by the company was able to boost the antibody response of a COVID-19 vaccine more than 100 times.
In a study published in Nature , Baidu ( BIDU ) researchers said the AI algorithm, known as LinearDesign, was able to create "highly stable" messenger RNA sequences for the vaccines and ultimately boost the efficacy of the vaccines by 128 times.
In an email to Seeking Alpha, a Baidu ( BIDU ) spokesman said the design capabilities of LinearDesign could be applied to other vaccines and treatments in the future.
The COVID-19 enhancement from its AI is one sign that Baidu's ( BIDU ) research into artificial intelligence may pay off.
Earlier this week, Bernstein analyst Boris Van upgraded Baidu ( BIDU ) shares outperform, citing the potential opportunities from AI technology.
With Baidu ( BIDU ) building up its AI services, Van said new product demonstrations "give us better clarity on product feature improvements" enough to raise his long-term revenue from search to 6% to 8% from 2% to 3%.
"A day in GPT is a year," Van said, adding that Baidu's ( BIDU ) management "seem to have learnt from [their] mistakes and [are now] able to test and learn, fail fast and move on.
Baidu ( BIDU ) shares fell around 0.7% to $116.71 in mid-day trading on Wednesday.
More on Baidu and Chinese tech
- Baidu shares edge north; Bernstein says AI offers 'a new lease on life'
- Alibaba shares lead Chinese tech losses as senators call for cloud sanctions
- Baidu rises as it unveils new advanced driving updates
For further details see:
Baidu says AI algorithm increased COVID vaccine antibody response 128 times